Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326624 · ClinicalTrials.gov registry record
Study of the Wearable Defibrillator in Heart-Failure Patients
A clinical trial, sponsored by Zoll Medical Corporation.
- Completed
- Registry status
- 25
- Enrollment target
NCT01326624: Completed study, sponsored by Zoll Medical Corporation.
NCT01326624 is a clinical trial that has completed, run by Zoll Medical Corporation. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01326624 has completed, sponsored by Zoll Medical Corporation.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of wearable defibrillator use in patients with left ventricular dysfunction or advanced heart failure symptoms, who have a high-risk for sudden cardiac death but are either not eligible for an implantable defibrillator under current guidelines or are not able to receive the device due to their condition.
Interventions
- DEVICE wearable defibrillator (LifeVest)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-03 |
| Est. Completion | 2017-12 |
What the finished NCT01326624 record still lists
NCT01326624 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which wearable defibrillator (LifeVest) is the first listed.
NCT01326624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01326624 about?
NCT01326624 is a clinical study titled "Study of the Wearable Defibrillator in Heart-Failure Patients". The purpose of the study is to evaluate the safety and efficacy of wearable defibrillator use in patients with left ventricular dysfunction or advanced heart failure symptoms, who have a high-risk for sudden cardiac death but are either not eligible for an implantable defibrillator under current gui...
What is the current status of trial NCT01326624?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2011-03. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01326624?
The interventions under investigation include: wearable defibrillator (LifeVest) (DEVICE).
Who is sponsoring clinical trial NCT01326624?
This trial is sponsored by Zoll Medical Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia